Data backs Vasca's haemodialysis access system:
This article was originally published in Clinica
Executive Summary
Vasca says that a multicentre clinical study has shown that patients using its LifeSite haemodialysis access system experienced significantly fewer device-related adverse events and complications during a 12-month follow-up period than those using a standard haemodialysis catheter. Patients treated with the LifeSite system were also significantly more likely to still be using the device a year later than those using the standard catheter, says the Tewksbury, Massachusetts firm. The LifeSite device is a totally subcutaneous haemodialysis access system. It was cleared for sale in the US in 2000.